Endocannabinoids and Mental Disorders.Handb Exp Pharmacol. 2015; 231:261-83.HE
Abstract
Preclinical and clinical data fully support the involvement of the endocannabinoid system in the etiopathogenesis of several mental diseases. In this review we will briefly summarize the most common alterations in the endocannabinoid system, in terms of cannabinoid receptors and endocannabinoid levels, present in mood disorders (anxiety, posttraumatic stress disorder, depression, bipolar disorder, and suicidality) as well as psychosis (schizophrenia) and autism. The arising picture for each pathology is not always straightforward; however, both animal and human studies seem to suggest that pharmacological modulation of this system might represent a novel approach for treatment.
Links
MeSH
Pub Type(s)
Journal Article
Review
Language
eng
PubMed ID
26408164
Citation
Rubino, Tiziana, et al. "Endocannabinoids and Mental Disorders." Handbook of Experimental Pharmacology, vol. 231, 2015, pp. 261-83.
Rubino T, Zamberletti E, Parolaro D. Endocannabinoids and Mental Disorders. Handb Exp Pharmacol. 2015;231:261-83.
Rubino, T., Zamberletti, E., & Parolaro, D. (2015). Endocannabinoids and Mental Disorders. Handbook of Experimental Pharmacology, 231, 261-83. https://doi.org/10.1007/978-3-319-20825-1_9
Rubino T, Zamberletti E, Parolaro D. Endocannabinoids and Mental Disorders. Handb Exp Pharmacol. 2015;231:261-83. PubMed PMID: 26408164.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Endocannabinoids and Mental Disorders.
AU - Rubino,Tiziana,
AU - Zamberletti,Erica,
AU - Parolaro,Daniela,
PY - 2015/9/27/entrez
PY - 2015/9/27/pubmed
PY - 2015/12/19/medline
KW - Autism
KW - Bipolar disorder and suicidality
KW - Depression
KW - Endocannabinoid system anxiety
KW - Posttraumatic stress disorder
KW - Schizophrenia
SP - 261
EP - 83
JF - Handbook of experimental pharmacology
JO - Handb Exp Pharmacol
VL - 231
N2 - Preclinical and clinical data fully support the involvement of the endocannabinoid system in the etiopathogenesis of several mental diseases. In this review we will briefly summarize the most common alterations in the endocannabinoid system, in terms of cannabinoid receptors and endocannabinoid levels, present in mood disorders (anxiety, posttraumatic stress disorder, depression, bipolar disorder, and suicidality) as well as psychosis (schizophrenia) and autism. The arising picture for each pathology is not always straightforward; however, both animal and human studies seem to suggest that pharmacological modulation of this system might represent a novel approach for treatment.
SN - 0171-2004
UR - https://www.unboundmedicine.com/medline/citation/26408164/Endocannabinoids_and_Mental_Disorders_
L2 - https://dx.doi.org/10.1007/978-3-319-20825-1_9
DB - PRIME
DP - Unbound Medicine
ER -